Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.59 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.56 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.56 |
| ▸ | CHEK2 | O96017 | 7/20 | 0.55 |
| ▸ | BCHE | P06276 | 2/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | ACACB | O00763 | 2/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
| ▸ | ACACA | Q13085 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19970783 | 0.92 | ENPP2 (0.56) | MGLLENPP2ATXN2CHEK2ACACB | |
| SCHEMBL19970809 | 0.92 | ACACB (0.52) | MGLLENPP2ATXN2CHEK2BCHE | |
| SCHEMBL19970761 | 0.88 | ACACB (0.53) | MGLLENPP2ATXN2CHEK2ACACB | |
| SCHEMBL20765540 | 0.87 | ENPP2 (0.57) | ENPP2ATXN2BCHEACHEACACB | |
| SCHEMBL19986744 | 0.85 | MGLL (0.57) | MGLLCHEK2BCHEACHEACACB | |
| SCHEMBL19970835 | 0.85 | BCHE (0.53) | CHEK2BCHEACHEGRIN2BHDAC3 | |
| SCHEMBL19970808 | 0.84 | ENPP2 (0.51) | MGLLENPP2ATXN2ACACBGRIN2B | |
| SCHEMBL19970792 | 0.83 | ENPP2 (0.54) | MGLLENPP2ATXN2ACACBGRIN2B | |
| SCHEMBL21843704 | 0.82 | HPGD (0.70) | MGLLCHEK2ACACBACACAHPGD | |
| SCHEMBL16619560 | 0.81 | MGLL (0.65) | MGLLCHEK2ACACBACACAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019038683-A1 | COMPOUNDS TARGETING TANDEM BRCT DOMAINS OF BRCA1, COMPOSITIONS AND METHODS THEREOF | INSTITUTE FOR STEM CELL BIOLOGY AND REGENERATIVE MEDICINE (IN) | 2019-02-28 | — | — | WO | claimed |
| US-11479571-B2 | Benzimidazol derivatives for treating filovirus infection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-10-25 | — | — | US | disclosed |
| US-20210292350-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | UNIVERSITE D'ORLEANS (FR) | 2021-09-23 | — | — | US | disclosed |
| US-20210292350-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | UNIVERSITE D'ORLEANS (FR) | 2021-09-23 | — | — | US | disclosed |
| WO-2019038683-A1 | COMPOUNDS TARGETING TANDEM BRCT DOMAINS OF BRCA1, COMPOSITIONS AND METHODS THEREOF | INSTITUTE FOR STEM CELL BIOLOGY AND REGENERATIVE MEDICINE (IN) | 2019-02-28 | — | — | WO | disclosed |
| WO-2018050771-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-22 | — | — | WO | disclosed |
| EP-3296297-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-21 | — | — | EP | disclosed |
| EP-3296297-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292350-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | FIP1L1, ZC3HAV1, MAVS | MGLL 2286/4885ENPP2 4368/4885ATXN2 4829/4885 |
| US-11479571-B2 | Benzimidazol derivatives for treating filovirus infection | FIP1L1, ZC3HAV1, MAVS | MGLL 2286/4885ENPP2 4368/4885ATXN2 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.